Psoriasis

Medicare beneficiaries with psoriasis and psoriatic arthritis were found to pay high annual out-of-pocket (OOP) costs for treatment, which researchers attributed to rising drug prices and reliance on co-insurance for patient cost-sharing.

Discontinued use and high dosage of alpha-glucosidase inhibitors in combination with metformin was shown to increase risk of psoriasis and psoriatic arthritis in patients with type 2 diabetes compared with those given only metformin.

Findings of a phase 2b study indicated that use of tildrakizumab was associated with significant improvements in joint and skin manifestations of patients with psoriatic arthritis (PsA), although improvement in symptoms of dactylitis and enthesitis were not observed.

By year 5 of therapy with disease-modifying anti-rheumatic drugs (DMARDs), only about one-third of patients with psoriatic arthritis (PsA) were expected to be continuing with their therapy.

Patients with psoriasis who received biologic treatments were at significantly lower risk of developing psoriatic arthritis, with women representing a potentially at-risk group.

Physical activity was significantly associated with cardiorespiratory fitness and pulse wave velocity, a preclinical indicator of future cardiovascular disease risk, in patients with psoriasis.

A recent study aimed to understand whether psoriasis and psoriatic arthritis are independent risk factors for coronary calcification and coronary artery disease. It found both correlate with higher rates of calcification, but only psoriasis was linked with severe calcification and disease.

A new prospective cohort study suggests joint pain, rather than skin pain or disease severity, correlates with greater use of analgesics.

Taiwanese patients with uveitis were shown to be at greater risk of developing psoriasis and psoriatic arthritis than the general population, and hypertension, diabetes, and obesity were more prominent in these populations as well.

August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.

Patients with psoriatic arthritis and rheumatoid arthritis who were obese were shown to present with significantly lower quality of life (QOL) and worse disease activity than those with normal weight.

New users of infliximab and adalimumab who had moderate to severe psoriasis exhibited an increased risk of hospitalization due to serious infection compared with etanercept users, with use of ustekinumab conversely linked with a decreased risk.

Researchers investigated whether responses to questionnaires on psoriasis and atopic dermatitis prevalence remained consistent over time.

Low cardiorespiratory fitness among young adult men was significantly associated with an increased risk of psoriasis and psoriatic arthritis over 3 decades.

The new report may help explain why patients with psoriasis have a higher risk of cardiovascular problems.

Psoriasis is prevalent among more than 7.5 million adults in the United States, a new study says.

A new report suggests patients with persistent nail psoriasis may benefit from biologics like tildrakizumab.

Recent reports document new COVID-19 guidance for people with psoriatic disease, positive safety and efficacy results for guselkumab, and findings linking the C-Jun protein with psoriasis.

Alcohol abuse, obesity, and the use of systemic therapies instead of biologics were all linked with poor response among individuals with psoriasis.

Three biologics appeared to increase herpes zoster risk, but 2 other therapies were shown to lower the risk, according to a study of patients in a Taiwanese national database.

Results of a systematic review and meta-analysis point to higher rates of metabolic syndrome among patients with psoriatic arthritis.

Both conditions involve a genetic predisposition as well as immune pathways that are triggered by environmental factors.

A review detailed the initial steps taken into personalized therapeutic options for psoriatic arthritis.

Generalized pustular psoriasis (GPP) may have therapies in a few years; how patients define remission in psoriatic arthritis (PsA).

A case of a patient with untreated psoriasis and nonischemic dilated cardiomyopathy (NIDCM) prompted clinicians to encourage study of the rare combination of disease.